Actively Recruiting

Age: 18Years +
All Genders
NCT07365930

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Led by Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Updated on 2026-02-05

350

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

Sponsors

I

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Lead Sponsor

R

Roche Pharma AG

Collaborating Sponsor

AI-Summary

What this Trial Is About

The NISTIPS TRITICC-4 study is a prospective, multicentre, non-interventional cohort study to analyze the effectiveness of transjugular intrahepatic portosystemic shunting (TIPS) in patients with Hepatocellular carcinoma (HCC) receiving atezolizumab plus bevacizumab as first-line treatment. It will further characterize the effectiveness of atezolizumab and bevacizumab therapy, investigate post-market safety and evaluate health-related quality in HCC patient cohorts with or without TIPS in a real-world setting.

CONDITIONS

Official Title

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients 18 years or older
  • Histologically confirmed locally advanced, metastatic, or unresectable hepatocellular carcinoma
  • Presence of liver cirrhosis confirmed by histology, liver stiffness, ultrasound, endoscopy, or blood tests
  • Disease not suitable for curative surgery or locoregional therapies, or progressive disease after such treatments
  • Decision made by treating physician to use atezolizumab plus bevacizumab with or without TIPS
  • Patients who have received 1-2 cycles of atezolizumab plus bevacizumab before enrollment are eligible if treatment decisions are separate from study inclusion
Not Eligible

You will not qualify if you...

  • Lack of signed informed consent
  • Under 18 years old at time of consent
  • Inability to understand the implications of study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital of Düsseldorf

Düsseldorf, North Rhine-Westphalia, Germany, 40225

Actively Recruiting

Loading map...

Research Team

C

Christoph Roderburg, Professor

CONTACT

B

Bianca Zaepf

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here